Prexton Therapeutics is a biopharmaceutical company based in Geneva and Amsterdam developing novel therapeutic compounds for central nervous system (CNS) conditions, with a focus on Parkinson’s disease. The company uses a discovery platform that integrates molecular, behavioral and chemistry technologies to identify specific novel compounds; its lead product is Foliglurax (formerly PXT002331). Prexton intends to use the proceeds of its recent financing to fund two Phase II studies of Foliglurax in Parkinson’s disease, with trials starting in 2017 at specialist centers in Europe and the US. The company closed a €29 million Series B financing to support these programs. Prexton was founded in 2012 by Francois Conquet and Merck Ventures and is part of a Merck Ventures entrepreneurial partnership program that supports spin‑offs. The company also pursues application of its discovery platform to other brain disorders. Prexton Therapeutics is developing novel small molecules that target the metabotropic glutamate receptor 4 (mGluR4) to treat Parkinson’s disease and other CNS conditions. The company applies an integrated scientific approach that combines molecular, behavioral and chemistry technologies to address motor complications in Parkinson’s patients. Its lead programs use compounds originally licensed from Domain Therapeutics. Prexton closed a Series A financing of €8.7m ($10m), its first funding, which will support development up to completion of Phase 1. The company is led by CEO François Conquet and was founded in 2012 by Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program. Prexton is based in Geneva, Switzerland.

Total raised

$41M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2017